Cancer immunotherapy using NKG2D and DNAM-1 systems

Anticancer Research

Volumn 32, Issue 6, 2012, Pages 2241-2247

  Morisaki, Takashi ^a,b   Onishi, Hideya ^b   Katano, Mitsuo ^b  

^a Fukuoka General Cancer Clinic   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

CAK; Cytokine activated killer cells; DNAM 1; Immunotherapy; MICA B ULBP; Natural killer; NKG2D; Review; TNK

Indexed keywords

BORTEZOMIB; BUTYRIC ACID; CYTARABINE; DNAX ACCESSORY MOLECULE 1; DOXORUBICIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; MELPHALAN; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN; RETINOIC ACID; SORAFENIB; SUNITINIB; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; CD226 ANTIGEN; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; T LYMPHOCYTE ANTIGEN;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DNA REPLICATION; DOWN REGULATION; GENOTOXICITY; HUMAN; IMMUNE EVASION; NATURAL KILLER CELL; OPSONIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; UPREGULATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; NEOPLASM;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 84864530880     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature 480: 480-489, 2011.
2. Dougan M and Dranoff G: Immune therapy for cancer. Ann Rev Immunol 27: 83-117, 2009.
3. Gabrilovich DI and Nagaraj S: Myeloid-derived-suppressor cells as regulators of the immune system. Nat Rev Immmnol 9: 162-174, 2009.
4. Rabinovich GA, Gabrilovich D and Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296, 2007.
5. Bonertz A, Weitz J, Pietsch D-H K, Rahbari NN, Schlude C, Ge Y, Juenger S, Vlodavsky I, Khazaie K, Jaeger D, Reissfelder C, Antolovic D, Aigner M, Koch M and Beckhove P: Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 119: 3311-3321, 2009.
6. Dudley ME and Rosenberg SA: Adoptive cell transfer therapy. Semin Oncol 34: 524-531, 2007.
7. June CH: Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476, 2007.
8. Eagle RA and Trowsdale J: Promiscuity and the single receptor: NKG2D. Nature Rev Immunol 7: 737-743, 2007.
9. Nausch N and Cerwenka A: NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958, 2008.
10. Ho EL, Heusel JW, Brown MG, Matsumoto K, Scalzo AA and Yokoyama WM: Murine NKG2D and CD94 are clustered within the natural killer complex and are expressed independently in natural killer cells. Proc Natl Acad Sci USA 95: 6320-6325, 1998.
11. Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781-790, 2003.
12. Champsaur M and Lanier LL: Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235: 267-285, 2010.
13. Gasser S, Orsulic S, Brown EJ and Raulet DH: The DNA damage pathway regulates innate immune system ligands for the NKG2D receptor. Nature 436: 1186-1190, 2005.
14. Ostberg JR, Dayanc BE, Yuan M, Oflazoglu E and Repasky EA: Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells. J Leukoc Biol 82: 1322-1331, 2007.
15. Park MJ, Bae JH, Chung JS, Kim SH and Kang CD: Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy. Immunol Invest 40: 367-382, 2011.
16. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL and Phillips JH: An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732, 1999.
17. Guerra N, Tan YX, Jonker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NR and Raulet DH: NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580, 2008.
18. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL and Phillips JH: DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4: 573-581, 1996.
19. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moetta L, Lopez M and Moretta A: Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198: 557-567, 2003.
20. Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S, Miyamoto A, Onodera M, Sumida T, Nakauchi H, Miyoshi H and Shibuya A: CD226 (DNAM-1) is involved in lymphocyte function-associated-antigen 1 costimulatory signal for naïve T-cell differentiation and proliferation. J Exp Med 198: 1829-1839, 2003.
21. Gilfillan S, Chan CJ, Cella CM, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ and Colonna M: DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205: 2965-2973,2008.
22. Carlsten M, Björkström N, Norell H, Bryceon Y, van Hall T, Baumann BC, Hanson M, Schedvins K, Kiessling R, Ljunggren H-G and Malmberg K-J: DNAX accessory molecule-1-mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 67: 1317-1325, 2007.
23. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, Bottino C and Moretta A: Natural killer cell-mediated killing of freshly isolated neuroblastoma cell: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 64: 9180-9184, 2004.
24. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S, Yasui T, Kikutani H, Shibuya K and Shibuya A: Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 205: 2959-2964, 2008.
25. Salih HR, Rammensee H-G and Steinle A: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-4102, 2002.
26. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, Strong RK, Groh V and Spies T: Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447: 482-486, 2007.
27. Li H, Han Y, Guo Q, Zhang M and Cao X: Cancer-expanded myeloid-derived suppressor cells induce anergy NK cells through membrane-bound TGF-beta 1. J Immunol 182: 240-249, 2009.
28. Lee JC, Lee KM, Kim DW and Heo DS: Elevated TGF-beta 1 secretion and down-modulation of NKG2D underlines impaired NK cytotoxicity in cancer patients. J Immunol 172: 7335-7340, 2004.
29. Saito H, Osaki T and Ikeguchi M: Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. Gastric Cancer 15: 27-33, 2012.
30. Mirjačić MK, Konjević G, Babović N and Inić M: The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients. J Surg Res 171: 637-649, 2011.
31. Caristen M, Baumann BC, Simonsson M, Jadersten M, Forsblom AM, Hammarstedt C, Bryceson YT, Ljunggren HG, Hellstrom-Lidberg E and Malmberg KJ: Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia 24: 1607-1616, 2010.
32. Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J and Sun W: Clinical significance of immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 28: 466-474, 2011.
33. Mamessier E, Sylvain A, Thibult M-L, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, André P, Romagné F, Thibaut G, Viens P, Birnbaum D, Bertucci F, Moretta A and Olive D: Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 121: 3609-3622, 2011.
34. Osaki T, Saito H, Yoshikawa T, Matsumoto S, Tatebe S, Tsujitani S and Ikeguchi M: Decreased NKG2D expression on CD8+T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res 13: 382-387, 2007.
35. Shen Y, Lu C, Tian W, Wang L, Cui B, Jiao Y, Ma C, Ju Y, Zhu L, Shao C, Liu X, Wang J, Zhang B and Lu Z: Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer. Int J Oncol 40: 1285-1290, 2012.
36. Maccalli C, Scaramuzza S and Parmiani G: TNK cells (NKG2D+CD8T+ or CD4+ T lymphocytes) in the control of human tumors. Cancer Immunol Immnother 58: 801-808, 2009.
37. Verneris MR, Karimi M, Baker J, Jayaswal A and Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T-cells. Blood 103: 3065-3072, 2004.
38. Karimi M, Cao TM, Baker JA, Verneris MR, Soares L and Negrin RS: Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+T cells and NK cells. J Immunol 175: 7819-7828, 2005.
39. Pievani A, Borleri G, pende D, Moretta L, Rambaldi A, Golay J and Introna M: Dual functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118: 3301-3310, 2011.
40. Groh V, Steinle A, Bauer S and Spies T: Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279:1737-1740, 1998.
41. Zhang C, Wang Y, Zhou Z, Zhang J and Tian Z: Sodium butyrate upregulates expression of NKG2D ligand MICA/B in Hela and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58: 1275-1285, 2009.
42. Ogbomo H, Michaelis M, Klassert D, Doerr HM, and Cinatl Jr. J: Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia 10: 1402-1410, 2008.
43. Tang K-F, He C-X, Zeng G-Li, Wu J, Song G-B, Shi Y-S, Zhang W-G, Huang A-L, Steinle A and Ren H: Induction of MHC Class I-related chain B (MICB) by 5-aza-2′-deoxycytidine. Biochem Biophys Res Com 370: 578-583, 2008.
44. Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M and Salih HR: Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 14: 3520-3528, 2008.
45. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Stenle A and Salih HR: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329, 2005.
46. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Nishioka T, Fukunaga S, Futani H, Okamura H and Terada N: Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol Rep 24: 1621-1627, 2010.
47. Skov S, Pederson MT, Andresen A, Straten PT, Woetmann A and Ødum N: Cancer Cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC Class I-related chain A and B. Cancer Res 65: 11136-11145, 2005.
48. Huang Y, Wang Y, Li Y, Guo K and He Y: Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J Cancer Res Clin Oncol 137: 829-837, 2010.
49. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y and Hayashi N: Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 104: 354-361, 2003.
50. Morisaki T, Onishi H, Koya N, Kiyata A, Tanaka H, Umebayashi M, Ogino T, Nagamatsu I and Katano M: Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via NKG2D-MICA/B system Anticancer Res 31: 2505-2510, 2011.
51. Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z and Nakao S: Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci 101: 609-615, 2010.
52. Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A, and Cippitelli M: Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol 183: 4385-4394, 2009.
53. Butler JE, Moore MB, Presnell SR, Chan H-W, Chalupny NJ and Lutz CT: Proteasome regulation of ULBP1 transcription. J Immunol 182: 6600-6609, 2009.
54. Chávez-Blanco A, De la Cruz-Hernández E, Dominguez GI, Rodríguez-Cortez O, Alatorre B, Pérez-Cárdenas E, Chacon-Salinas R, Trjo-Becerril C, Taja-Chayeb L, Trujillo JE, Contreras-Paredes A and Duenas-González A: Upregulation of NKG2D ligands and enhanced natural killer cytotoxicity by hydralazine and valproate. Int J Oncol 39: 1491-1499, 2011.
55. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foá R and Santoni A: ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113: 3503-3511, 2009.
56. Jinushi M, Hodi FS and Dranoff G: Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci USA 103: 9190-9195, 2006.
57. Germain C, Campigna E, Salhi I, Morisseau S, Navarro-Teulon I, Mach JP, Pèlegrin and Robert B: Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein. Protein Eng Des Sel 21: 665-672, 2008.
58. Von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, Simhadri VR, Draube A, Reiser M, Purr I, Hallek M and Engert A: A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma. Blood 107: 1955-1962, 2006.
59. Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A and Hayashi N: Sorafenib inhibits the shedding major histocompability complex class-I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 51: 1264-1273, 2010.
60. Huang B, Sikorski R, Sampath P and Thorne SH: Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 34: 289-296, 2011.